Grimm, S. E., Fayter, D., Ramaekers, B. L. T., Petersohn, S., Riemsma, R., Armstrong, N., . . . Joore, M. A. (2019). Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics.
Citación estilo ChicagoGrimm, Sabine E., et al. "Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal." Pharmacoeconomics 2019.
Cita MLAGrimm, Sabine E., et al. "Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal." Pharmacoeconomics 2019.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.